Pharmaceutical

Gilead gains EC approval for metastatic breast cancer drug Trodelvy

Gilead Sciences has received approval from EC for Trodelvy, for pre-treated HR-positive, HER2-negative metastatic breast cancer.

Jul 29, 2023 - 20:00
Gilead gains EC approval for metastatic breast cancer drug Trodelvy
Gilead Sciences has received approval from EC for Trodelvy, for pre-treated HR-positive, HER2-negative metastatic breast cancer.
Read the original article

Tags:

Previous Article

InSilicoTrials and Axoltis to develop drugs for neurological disorders

Next Article

How did hiring in the Indian pharma industry perform in Q2 2023

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Democrats urge government to rein in Medicare Advantage overpayments and denials

STAT+: Democrats urge government to rein in Medicare Ad...

Jan 26, 2024

STAT+: Digital tools helped lower blood pressure in marginalized patient groups

STAT+: Digital tools helped lower blood pressure in mar...

Feb 15, 2024

argenx wins EMA CHMP nod for subcutaneous Vyvgart in myasthenia gravis

argenx wins EMA CHMP nod for subcutaneous Vyvgart in my...

Sep 15, 2023